Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2011

Biopharma financing dropped in Q3 2011 to $1.3 billion, down from $6.3 billion in Q2. There were 20 M&A deals that totaled $30.9 billion, attributed mainly to the $27.7 million merger of PBMs Express Scripts and Medco. Almost a quarter of the alliances penned were for preclinical assets.

The third quarter of 2011 saw biopharmaceutical financings slump in both the number of transactions and the amount of money raised. The 61 financings that closed brought in $1.3 billion, well below Q2, in which 89 transactions raised $6.3 billion. (See Exhibit 1.) Follow-on public offerings led the pack in Q3, with $363 million gathered through only 10 deals. The two largest FOPOs together brought in close to half of that money – Zogenix Inc.’s $57.5 million [See Deal] and InterMune Inc.’s $94.4 million. [See Deal] Coincidentally, the biggest transaction this quarter was InterMune’s concurrent $131 million debt offering. [See Deal] The company’s financings will be used for the European launch of the idiopathic pulmonary fibrosis drug Esbriet (pirfenidone) – which was acquired from Marnac Inc. in 2007 [See Deal] – and to fund the Phase III ASCEND trial in the US. [See Deal] The remainder of the follow-ons went to cancer-focused companies – BioSante Pharmaceuticals Inc., [See Deal]Delcath Systems Inc., [See Deal]CytRx Corp., [See Deal]Cyclacel Pharmaceuticals Inc., [See Deal] and Agenus Inc.[See Deal]

Exhibit 1

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deal-Making

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Deals Shaping The Industry, May 2025

 
• By 

An interactive look at pharma, medtech and diagnostics deals made during May 2025. Data courtesy of Biomedtracker.

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By 

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

Deals In Depth: April 2025

 
• By 

Four $1bn+ alliances were penned in April, and one exceeded $2bn.

More from In Vivo

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By 

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.